Sogroya® (somapacitan-beco) injection Sogroya® (somapacitan-beco) injection

For Health Care Professionals

Sign up icon
Sign up icon

Results and safety for children taking Sogroya® for OTHER SPECIFIC growth-related Conditions

In addition to growth hormone deficiency (GHD) in patients 2.5 years and older, Sogroya® is the first and only once-weekly growth hormone treatment approved for children 2.5 years and older with Idiopathic Short Stature (ISS), who are not growing and have Noonan Syndrome (NS), and who are short (in stature) and were born small (Small for Gestational Age-SGA) with no catch-up growth by age 2.

 

Is Sogroya® safe and effective for my child?

For kids with ISS, NS, or born SGA, getting their growth hormone injection once a week instead of every day could be a game-changer. Ask your doctor if once-weekly Sogroya® could be the right choice for your family. To learn more about its efficacy and safety, keep reading.

Sogroya® is used to treat children 2.5 years of age and older who: are short (in stature) and were born small (Small for Gestational Age-SGA) and have not caught up in growth by age 2 years; are not growing and have Noonan Syndrome (NS); and have Idiopathic Short Stature (ISS).

Idiopathic Short Stature (ISS)

In a 1-year (52-week) study of 88 children who had never been treated for Idiopathic Short Stature (ISS), Sogroya® was compared with a daily growth hormone (GH) treatment called somatropin.

The main goal of this study, REAL8, was to see if children with ISS who took Sogroya® once per week grew at a similar rate as children who took the daily GH treatment.

From year 0 to year 1:

Children taking Sogroya® (0.24 mg/kg/week) grew ~4 inches (10.2 cm), on average, at 1 year.

Children taking daily GH (0.050 mg/kg/day) grew ~4.1 inches (10.5 cm), on average, at 1 year.

These results are from the REAL8 main trial phase (Week 0 to Week 52). A total of 88 children 2.8-10.8 years of age with a confirmed diagnosis of ISS were randomized to receive Sogroya® 0.24 mg/kg/week or daily somatropin 0.050 mg/kg/day. In the US, a 0.05 mg/kg/day dose of daily somatropin is considered less than the maximum dose (0.067 mg/kg/day) approved for use for children with ISS.

Sogroya® has a proven safety profile

The following side effects occurred in 10% or more of children being treated with Sogroya® for ISS:

  • Respiratory tract infection
  • Common cold
  • Ear infection
  • Diarrhea
  • Headache
  • Reaction to injection

Talk to your child’s doctor for medical advice about these and other possible side effects.

Sogroya® is the first and only once-weekly GH treatment approved for children (2.5 years and older) with ISS.

Small for Gestational Age (SGA)

In a 1-year (52-week) study of 142 children who had never been treated for being Small for Gestational Age (SGA), Sogroya® was compared with a daily growth hormone (GH) treatment called somatropin.

The main goal of this study, REAL8, was to see if children who are SGA and who took Sogroya® once per week grew at a similar rate as children who took the daily GH treatment.

From year 0 to year 1:

Children taking Sogroya® (0.24 mg/kg/wk) grew ~4.3 inches (11 cm), on average, at 1 year.

Children taking daily GH (0.067 mg/kg/day) grew ~4.4 inches (11.1 cm), on average, at 1 year.

Children taking daily GH (0.035 mg/kg/day) grew ~3.7 inches (9.4 cm), on average, at 1 year.

These results are from the REAL8 main trial phase (Week 0 to Week 52). A total of 142 children 2.6-10.7 years of age with a confirmed diagnosis of SGA were randomized to receive Sogroya® 0.24 mg/kg/week, daily somatropin 0.035 mg/kg/day or daily somatropin 0.067 mg/kg/day. In the US, a 0.035 mg/kg/day dose of daily somatropin is less than maximum dose (0.067 mg/kg/day) approved for use in pediatric patients with SGA.

Sogroya® has a proven safety profile

The following side effects occurred in 10% or more of children being treated with Sogroya® for SGA:

  • Common cold
  • Respiratory tract infection
  • Fever
  • Cough
  • Ear infection
  • Diarrhea
  • Vomiting

Talk to your child’s doctor for medical advice about these and other possible side effects.

Sogroya® is the first and only once-weekly GH treatment approved for children (2.5 years and older) born SGA and have not caught up in growth by age 2 years.

Noonan Syndrome (NS)

In a 1-year (52-week) study of 77 children who had never been treated for Noonan Syndrome (NS), Sogroya® was compared with a daily growth hormone (GH) treatment called somatropin.

The main goal of this study, REAL8, was to see if children with NS who took Sogroya® once per week grew at a similar rate as children who took the daily GH treatment.

From year 0 to year 1:

Children taking Sogroya® (0.24 mg/kg/wk) grew ~4.1 inches (10.4 cm), on average, at 1 year.

Children taking daily GH (0.050 mg/kg/day) grew ~3.6 inches (9.2 cm), on average, at 1 year.

These results are from the REAL8 main trial phase (Week 0 to Week 52). A total of 77 children 2 to 11.1 years of age with a confirmed diagnosis of NS were randomized to receive Sogroya® 0.24 mg/kg/week or daily somatropin 0.050 mg/kg/day. In the US, 0.05 mg/kg/day of daily somatropin is less than maximum dose (0.066 mg/kg/day) approved for use in pediatric patients with NS.

Sogroya® has a proven safety profile

The following side effects occurred in 10% or more of children being treated with Sogroya® for NS:

  • Respiratory tract infection
  • Common cold
  • Diarrhea
  • Ear infection
  • Cough
  • Vomiting
  • Fever
  • Headache

Talk to your child’s doctor for medical advice about these and other possible side effects.

Sogroya® is the first and only once-weekly GH treatment approved for children (2.5 years and older) who are short in stature with NS.

How to use Sogroya® for children

Use our helpful tools for learning how to take Sogroya®.

Find out more

Actor portrayal

Daily injections can be a challenge

If your family struggles with daily growth hormone injections, you’re not alone. A once-weekly option might be a better fit.

Find out more

Actor portrayal

Show more Show less

Important Safety Information

Do not use Sogroya® if:

  • you have a critical illness caused by certain types of heart or stomach surgery, trauma or breathing problems
  • you have cancer or other tumors
  • you are allergic to somapacitan-beco or any of the ingredients in Sogroya®
  • your healthcare provider tells you that you have certain types of eye problems caused by diabetes
  • you are a child with closed bone growth plates
  • you are a child with Prader-Willi syndrome who is severely obese or has breathing problems including sleep apnea (briefly stopping breathing during sleep)

Before taking Sogroya®, tell your healthcare provider about all of your medical conditions, including if you:

  • have had heart or stomach surgery, trauma, or serious breathing problems
  • have had cancer or any tumor
  • have diabetes
  • have adrenal gland problems
  • are taking replacement therapy with glucocorticoids
  • have thyroid gland problems
  • have liver problems
  • are a child with a history of worsening of curvature of the spine (scoliosis)
  • are pregnant or plan to become pregnant. It is not known if Sogroya® will harm your unborn baby. Talk to your healthcare provider if you are pregnant or plan to become pregnant
  • are breastfeeding or plan to breastfeed. It is not known if Sogroya® passes into your breast milk. You and your healthcare provider should decide if you will take Sogroya® while you breastfeed

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Sogroya® may affect the way some medicines work, and some medicines may affect how Sogroya® works.

How should I use Sogroya®?

  • Use Sogroya® exactly as your healthcare provider tells you to
  • Use Sogroya® 1 time each week
  • If you miss a dose of Sogroya®, the missed dose can be taken within 3 days (72 hours) after the scheduled dosing day. One-time weekly dosing for the next dose can be started again on the regularly scheduled dosing day
  • If more than 3 days (72 hours) have passed, skip the missed dose, and take your next dose on the regularly scheduled dosing day
  • Sogroya® pens are for use by 1 person only
  • Do not share your Sogroya® pens and needles with another person, even if the needle has been changed. You may give another person an infection or get an infection from them

What are the possible side effects of Sogroya®?

Sogroya® may cause serious side effects, including:

  • high risk of death in people who have critical illnesses because of heart or stomach surgery, trauma, or serious breathing problems
  • increased risk of growth of cancer or a tumor that is already present and increased risk of the return of cancer or a tumor in people who were treated with radiation to the brain or head as children and who developed low growth hormone problems. Your or your child’s healthcare provider will need to monitor you or your child for a return of cancer or a tumor. Contact the healthcare provider if you or your child start to have sudden changes in behavior, headaches, vision problems, or changes in moles, birthmarks, or the color of your or your child’s skin
  • new or worsening high blood sugar (hyperglycemia) or diabetes. You or your child’s blood sugar may need to be monitored during treatment with Sogroya®
  • increase in pressure in the skull (intracranial hypertension). If you or your child have headaches, eye problems, nausea or vomiting, contact the healthcare provider
  • serious allergic reactions. Get medical help right away if you or your child have the following symptoms: swelling of your face, lips, mouth, or tongue, trouble breathing, wheezing, severe itching, skin rashes, redness, or swelling, dizziness or fainting, fast heartbeat or pounding in your chest, sweating
  • your or your child’s body holding too much fluid (fluid retention) such as swelling in the hands and feet, pain in your or your child’s joints or muscles or nerve problems that cause pain, burning or tingling in the hands, arms, legs, and feet. Tell your or your child’s healthcare provider if you or your child have any of these signs or symptoms of fluid retention
  • decrease in a hormone called cortisol. The healthcare provider will do blood tests to check your or your child’s cortisol levels. Tell your or your child’s healthcare provider if you or your child have darkening of the skin, severe fatigue, dizziness, weakness, or weight loss
  • decrease in thyroid hormone levels. Decreased thyroid hormone levels may affect how well Sogroya® works. The healthcare provider will do blood tests to check you or your child’s thyroid hormone levels
  • severe and constant abdominal pain. This could be a sign of pancreatitis. Tell your or your child’s healthcare provider if you or your child has any new abdominal pain
  • loss of fat and tissue weakness in the area of skin you or your child inject. Talk to your or your child’s healthcare provider about rotating the areas where you or your child inject Sogroya®
  • worsening of curvature of the spine in children (scoliosis)
  • hip and knee pain or a limp in children (slipped capital femoral epiphysis). This may lead to a serious condition where bone tissue dies due to lack of blood supply (osteonecrosis). Get medical help right away if your child develops a limp or has hip or knee pain
  • high risk of sudden death in children with Prader-Willi syndrome who are severely obese or have breathing problems, including sleep apnea
  • increase in phosphorus, alkaline phosphatase, and parathyroid hormone levels in your blood. You or your child’s healthcare provider will do blood tests to check this

The most common side effects of Sogroya® in children include: cough, common cold, diarrhea, ear infection, headache, fever, pain in extremity, reaction to injection, respiratory tract infection, and vomiting 

The most common side effects of Sogroya® in adults include: back pain, joint pain, indigestion, sleep problems, dizziness, swelling of the tonsils (tonsillitis), swelling in the feet and hands (peripheral edema), vomiting, low cortisol levels (adrenal insufficiency), high blood pressure, increase in the level of an enzyme in your blood called creatine phosphokinase, weight gain, and low red blood cells (anemia)

Please click here for Sogroya® Prescribing Information.

Sogroya® is a prescription medication. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

What is Sogroya®?

  • Sogroya® (somapacitan-beco) injection 5 mg, 10 mg or 15 mg is a prescription medicine that contains human growth hormone, the same growth hormone made by the body. Sogroya® is given by injection under the skin (subcutaneous).
  • Sogroya® is used to treat children 2.5 years of age and older who:
    • are not growing because of low or no growth hormone
    • are short (in stature) and were born small (Small for Gestational Age-SGA) and have not caught up in growth by age 2 years
    • are not growing and have Noonan Syndrome (NS)
    • have Idiopathic Short Stature (ISS)
  • Sogroya® is used to treat adults who do not make enough growth hormone

What is Sogroya®?

  • Sogroya® (somapacitan-beco) injection 5 mg, 10 mg or 15 mg is a prescription medicine that contains human growth hormone, the same growth hormone made by the body. Sogroya® is given by injection under the skin (subcutaneous).
  • Sogroya® is used to treat children 2.5 years of age and older who:
    • are not growing because of low or no growth hormone
    • are short (in stature) and were born small (Small for Gestational Age-SGA) and have not caught up in growth by age 2 years
    • are not growing and have Noonan Syndrome (NS)
    • have Idiopathic Short Stature (ISS)
  • Sogroya® is used to treat adults who do not make enough growth hormone

Show more Show less
Show more Show less

What is Sogroya®?

  • Sogroya® (somapacitan-beco) injection 5 mg, 10 mg or 15 mg is a prescription medicine that contains human growth hormone, the same growth hormone made by the body. Sogroya® is given by injection under the skin (subcutaneous).
  • Sogroya® is used to treat children 2.5 years of age and older who:
    • are not growing because of low or no growth hormone
    • are short (in stature) and were born small (Small for Gestational Age-SGA) and have not caught up in growth by age 2 years
    • are not growing and have Noonan Syndrome (NS)
    • have Idiopathic Short Stature (ISS)
  • Sogroya® is used to treat adults who do not make enough growth hormone

What is Sogroya®?

  • Sogroya® (somapacitan-beco) injection 5 mg, 10 mg or 15 mg is a prescription medicine that contains human growth hormone, the same growth hormone made by the body. Sogroya® is given by injection under the skin (subcutaneous).
  • Sogroya® is used to treat children 2.5 years of age and older who:
    • are not growing because of low or no growth hormone
    • are short (in stature) and were born small (Small for Gestational Age-SGA) and have not caught up in growth by age 2 years
    • are not growing and have Noonan Syndrome (NS)
    • have Idiopathic Short Stature (ISS)
  • Sogroya® is used to treat adults who do not make enough growth hormone

Important Safety Information

Do not use Sogroya® if:

  • you have a critical illness caused by certain types of heart or stomach surgery, trauma or breathing problems
  • you have cancer or other tumors
  • you are allergic to somapacitan-beco or any of the ingredients in Sogroya®
  • your healthcare provider tells you that you have certain types of eye problems caused by diabetes
  • you are a child with closed bone growth plates
  • you are a child with Prader-Willi syndrome who is severely obese or has breathing problems including sleep apnea (briefly stopping breathing during sleep)

Important Safety Information

Do not use Sogroya® if:

  • you have a critical illness caused by certain types of heart or stomach surgery, trauma or breathing problems
  • you have cancer or other tumors
  • you are allergic to somapacitan-beco or any of the ingredients in Sogroya®
  • your healthcare provider tells you that you have certain types of eye problems caused by diabetes
  • you are a child with closed bone growth plates
  • you are a child with Prader-Willi syndrome who is severely obese or has breathing problems including sleep apnea (briefly stopping breathing during sleep)

Before taking Sogroya®, tell your healthcare provider about all of your medical conditions, including if you:

  • have had heart or stomach surgery, trauma, or serious breathing problems
  • have had cancer or any tumor
  • have diabetes
  • have adrenal gland problems
  • are taking replacement therapy with glucocorticoids
  • have thyroid gland problems
  • have liver problems
  • are a child with a history of worsening of curvature of the spine (scoliosis)
  • are pregnant or plan to become pregnant. It is not known if Sogroya® will harm your unborn baby. Talk to your healthcare provider if you are pregnant or plan to become pregnant
  • are breastfeeding or plan to breastfeed. It is not known if Sogroya® passes into your breast milk. You and your healthcare provider should decide if you will take Sogroya® while you breastfeed

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Sogroya® may affect the way some medicines work, and some medicines may affect how Sogroya® works.

How should I use Sogroya®?

  • Use Sogroya® exactly as your healthcare provider tells you to
  • Use Sogroya® 1 time each week
  • If you miss a dose of Sogroya®, the missed dose can be taken within 3 days (72 hours) after the scheduled dosing day. One-time weekly dosing for the next dose can be started again on the regularly scheduled dosing day
  • If more than 3 days (72 hours) have passed, skip the missed dose, and take your next dose on the regularly scheduled dosing day
  • Sogroya® pens are for use by 1 person only
  • Do not share your Sogroya® pens and needles with another person, even if the needle has been changed. You may give another person an infection or get an infection from them

What are the possible side effects of Sogroya®?

Sogroya® may cause serious side effects, including:

  • high risk of death in people who have critical illnesses because of heart or stomach surgery, trauma, or serious breathing problems
  • increased risk of growth of cancer or a tumor that is already present and increased risk of the return of cancer or a tumor in people who were treated with radiation to the brain or head as children and who developed low growth hormone problems. Your or your child’s healthcare provider will need to monitor you or your child for a return of cancer or a tumor. Contact the healthcare provider if you or your child start to have sudden changes in behavior, headaches, vision problems, or changes in moles, birthmarks, or the color of your or your child’s skin
  • new or worsening high blood sugar (hyperglycemia) or diabetes. You or your child’s blood sugar may need to be monitored during treatment with Sogroya®
  • increase in pressure in the skull (intracranial hypertension). If you or your child have headaches, eye problems, nausea or vomiting, contact the healthcare provider
  • serious allergic reactions. Get medical help right away if you or your child have the following symptoms: swelling of your face, lips, mouth, or tongue, trouble breathing, wheezing, severe itching, skin rashes, redness, or swelling, dizziness or fainting, fast heartbeat or pounding in your chest, sweating
  • your or your child’s body holding too much fluid (fluid retention) such as swelling in the hands and feet, pain in your or your child’s joints or muscles or nerve problems that cause pain, burning or tingling in the hands, arms, legs, and feet. Tell your or your child’s healthcare provider if you or your child have any of these signs or symptoms of fluid retention
  • decrease in a hormone called cortisol. The healthcare provider will do blood tests to check your or your child’s cortisol levels. Tell your or your child’s healthcare provider if you or your child have darkening of the skin, severe fatigue, dizziness, weakness, or weight loss
  • decrease in thyroid hormone levels. Decreased thyroid hormone levels may affect how well Sogroya® works. The healthcare provider will do blood tests to check you or your child’s thyroid hormone levels
  • severe and constant abdominal pain. This could be a sign of pancreatitis. Tell your or your child’s healthcare provider if you or your child has any new abdominal pain
  • loss of fat and tissue weakness in the area of skin you or your child inject. Talk to your or your child’s healthcare provider about rotating the areas where you or your child inject Sogroya®
  • worsening of curvature of the spine in children (scoliosis)
  • hip and knee pain or a limp in children (slipped capital femoral epiphysis). This may lead to a serious condition where bone tissue dies due to lack of blood supply (osteonecrosis). Get medical help right away if your child develops a limp or has hip or knee pain
  • high risk of sudden death in children with Prader-Willi syndrome who are severely obese or have breathing problems, including sleep apnea
  • increase in phosphorus, alkaline phosphatase, and parathyroid hormone levels in your blood. You or your child’s healthcare provider will do blood tests to check this

The most common side effects of Sogroya® in children include: cough, common cold, diarrhea, ear infection, headache, fever, pain in extremity, reaction to injection, respiratory tract infection, and vomiting 

The most common side effects of Sogroya® in adults include: back pain, joint pain, indigestion, sleep problems, dizziness, swelling of the tonsils (tonsillitis), swelling in the feet and hands (peripheral edema), vomiting, low cortisol levels (adrenal insufficiency), high blood pressure, increase in the level of an enzyme in your blood called creatine phosphokinase, weight gain, and low red blood cells (anemia)

Please click here for Sogroya® Prescribing Information.

Sogroya® is a prescription medication. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Important Safety Information

Do not use Sogroya® if:

  • you have a critical illness caused by certain types of heart or stomach surgery, trauma or breathing problems
  • you have cancer or other tumors
  • you are allergic to somapacitan-beco or any of the ingredients in Sogroya®
  • your healthcare provider tells you that you have certain types of eye problems caused by diabetes
  • you are a child with closed bone growth plates
  • you are a child with Prader-Willi syndrome who is severely obese or has breathing problems including sleep apnea (briefly stopping breathing during sleep)

Before taking Sogroya®, tell your healthcare provider about all of your medical conditions, including if you:

  • have had heart or stomach surgery, trauma, or serious breathing problems
  • have had cancer or any tumor
  • have diabetes
  • have adrenal gland problems
  • are taking replacement therapy with glucocorticoids
  • have thyroid gland problems
  • have liver problems
  • are a child with a history of worsening of curvature of the spine (scoliosis)
  • are pregnant or plan to become pregnant. It is not known if Sogroya® will harm your unborn baby. Talk to your healthcare provider if you are pregnant or plan to become pregnant
  • are breastfeeding or plan to breastfeed. It is not known if Sogroya® passes into your breast milk. You and your healthcare provider should decide if you will take Sogroya® while you breastfeed

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Sogroya® may affect the way some medicines work, and some medicines may affect how Sogroya® works.

How should I use Sogroya®?

  • Use Sogroya® exactly as your healthcare provider tells you to
  • Use Sogroya® 1 time each week
  • If you miss a dose of Sogroya®, the missed dose can be taken within 3 days (72 hours) after the scheduled dosing day. One-time weekly dosing for the next dose can be started again on the regularly scheduled dosing day
  • If more than 3 days (72 hours) have passed, skip the missed dose, and take your next dose on the regularly scheduled dosing day
  • Sogroya® pens are for use by 1 person only
  • Do not share your Sogroya® pens and needles with another person, even if the needle has been changed. You may give another person an infection or get an infection from them

What are the possible side effects of Sogroya®?

Sogroya® may cause serious side effects, including:

  • high risk of death in people who have critical illnesses because of heart or stomach surgery, trauma, or serious breathing problems
  • increased risk of growth of cancer or a tumor that is already present and increased risk of the return of cancer or a tumor in people who were treated with radiation to the brain or head as children and who developed low growth hormone problems. Your or your child’s healthcare provider will need to monitor you or your child for a return of cancer or a tumor. Contact the healthcare provider if you or your child start to have sudden changes in behavior, headaches, vision problems, or changes in moles, birthmarks, or the color of your or your child’s skin
  • new or worsening high blood sugar (hyperglycemia) or diabetes. You or your child’s blood sugar may need to be monitored during treatment with Sogroya®
  • increase in pressure in the skull (intracranial hypertension). If you or your child have headaches, eye problems, nausea or vomiting, contact the healthcare provider
  • serious allergic reactions. Get medical help right away if you or your child have the following symptoms: swelling of your face, lips, mouth, or tongue, trouble breathing, wheezing, severe itching, skin rashes, redness, or swelling, dizziness or fainting, fast heartbeat or pounding in your chest, sweating
  • your or your child’s body holding too much fluid (fluid retention) such as swelling in the hands and feet, pain in your or your child’s joints or muscles or nerve problems that cause pain, burning or tingling in the hands, arms, legs, and feet. Tell your or your child’s healthcare provider if you or your child have any of these signs or symptoms of fluid retention
  • decrease in a hormone called cortisol. The healthcare provider will do blood tests to check your or your child’s cortisol levels. Tell your or your child’s healthcare provider if you or your child have darkening of the skin, severe fatigue, dizziness, weakness, or weight loss
  • decrease in thyroid hormone levels. Decreased thyroid hormone levels may affect how well Sogroya® works. The healthcare provider will do blood tests to check you or your child’s thyroid hormone levels
  • severe and constant abdominal pain. This could be a sign of pancreatitis. Tell your or your child’s healthcare provider if you or your child has any new abdominal pain
  • loss of fat and tissue weakness in the area of skin you or your child inject. Talk to your or your child’s healthcare provider about rotating the areas where you or your child inject Sogroya®
  • worsening of curvature of the spine in children (scoliosis)
  • hip and knee pain or a limp in children (slipped capital femoral epiphysis). This may lead to a serious condition where bone tissue dies due to lack of blood supply (osteonecrosis). Get medical help right away if your child develops a limp or has hip or knee pain
  • high risk of sudden death in children with Prader-Willi syndrome who are severely obese or have breathing problems, including sleep apnea
  • increase in phosphorus, alkaline phosphatase, and parathyroid hormone levels in your blood. You or your child’s healthcare provider will do blood tests to check this

The most common side effects of Sogroya® in children include: cough, common cold, diarrhea, ear infection, headache, fever, pain in extremity, reaction to injection, respiratory tract infection, and vomiting 

The most common side effects of Sogroya® in adults include: back pain, joint pain, indigestion, sleep problems, dizziness, swelling of the tonsils (tonsillitis), swelling in the feet and hands (peripheral edema), vomiting, low cortisol levels (adrenal insufficiency), high blood pressure, increase in the level of an enzyme in your blood called creatine phosphokinase, weight gain, and low red blood cells (anemia)

Please click here for Sogroya® Prescribing Information.

Sogroya® is a prescription medication. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

What is Sogroya®?

  • Sogroya® (somapacitan-beco) injection 5 mg, 10 mg or 15 mg is a prescription medicine that contains human growth hormone, the same growth hormone made by the body. Sogroya® is given by injection under the skin (subcutaneous).
  • Sogroya® is used to treat children 2.5 years of age and older who:
    • are not growing because of low or no growth hormone
    • are short (in stature) and were born small (Small for Gestational Age-SGA) and have not caught up in growth by age 2 years
    • are not growing and have Noonan Syndrome (NS)
    • have Idiopathic Short Stature (ISS)
  • Sogroya® is used to treat adults who do not make enough growth hormone

What is Sogroya®?

  • Sogroya® (somapacitan-beco) injection 5 mg, 10 mg or 15 mg is a prescription medicine that contains human growth hormone, the same growth hormone made by the body. Sogroya® is given by injection under the skin (subcutaneous).
  • Sogroya® is used to treat children 2.5 years of age and older who:
    • are not growing because of low or no growth hormone
    • are short (in stature) and were born small (Small for Gestational Age-SGA) and have not caught up in growth by age 2 years
    • are not growing and have Noonan Syndrome (NS)
    • have Idiopathic Short Stature (ISS)
  • Sogroya® is used to treat adults who do not make enough growth hormone

Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, New Jersey 08536 U.S.A.
Sogroya® is a registered trademark of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.

© 2026 Novo Nordisk All rights reserved.  US25SOM00260 March 2026

You are about to leave Sogroya.com, a Novo Nordisk website

Click “Continue” to leave the site and come back to visit us another time. Click “Return to site” to stay and learn more about Sogroya® (somapacitan-beco) injection.

Continue

You are about to leave Sogroya.com, a Novo Nordisk website

Click “Continue” to leave the site. Novo Nordisk isn’t responsible for the following content. Come back to visit us another time.

Click “Return to site” to stay and learn more about Sogroya® (somapacitan-beco) injection.

Continue
Access Resources